Bisantrene in relapsed and refractory acute myelogenous leukemia

Antonio Spadea, Maria Concetta Petti, Maria Antonietta Aloespiriti, Giuseppe Avvisati, Cinzia De Gregoris, Paola Fazi, Roberto Latagliata, Sergio Amadori, Franco Mandelli

Research output: Contribution to journalArticlepeer-review


Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinical trials with acceptable extrahaematological toxicity. Seven patients (six males and one female, median age 41.8 years) received Bisantrene (250 mg/sqm/daily 1-7) as a single agent in relapsed or refractory leukemia. 5 out of 7 patients achieved complete remission, one attained partial remission and one was resistant. However, haematological toxicity was severe with prolonged myelosuppression. Hepatic toxicity was the main extrahaematological side effect and occurred in 3 of 7 patients, however all of them recovered within 40 days. No cardiovascular dysfunction occurred although all the patients had been heavily previously treated with anthracyclines. Our data confirm that Bisantrere is active in relapsed and refractory AML and suggest the need for larger clinical trials to better evaluate its efficacy.

Original languageEnglish
Pages (from-to)217-220
Number of pages4
JournalLeukemia and Lymphoma
Issue number3
Publication statusPublished - 1993


  • Bisantrene
  • Chemotherapy
  • Relapsed/refractory acute myelogenous leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Bisantrene in relapsed and refractory acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this